Cytokine-Induced Killer Cells for Resistant Malaria Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Plasmodium infections, particularly malaria caused by Plasmodium falciparum, are inadequate due to resistance and limited efficacy in some cases, necessitating a more effective therapeutic approach.

Innovation Solution

Cytokine-Induced Killer (CIK) cells, generated ex-vivo by incubating peripheral blood lymphocytes with anti-CD3 monoclonal antibody, interleukin-2, and interferon gamma, are used to target and eliminate Plasmodium-infected cells, offering a potential alternative for adoptive immunotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antimalarial medications are used, then treatment is provided, but resistance and limited efficacy occur

Engineering Contradiction:

Improve treatment efficacyVSAvoidparasite resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces conventional chemical antimalarial medications with a biological immunotherapy system. CIK cells (cytokine-induced killer cells) are generated from patient peripheral blood lymphocytes through in vitro culture with cytokines (IL-2, IFN-gamma, anti-CD3 antibody), then reinfused to mediate parasite elimination through cellular cytotoxicity and immunomodulation, substituting chemical therapy with a biological mechanism

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The therapy utilizes the patient's own peripheral blood lymphocytes as the source material for generating CIK cells. The cells are autologous, meaning they are derived from and returned to the same patient, eliminating the need for external cell sources and reducing immunological rejection risks while maintaining treatment efficacy

Inventive Principle:

Principle #25Self-service

2Reliability

If CIK cells are generated ex-vivo, then treatment efficacy is improved, but treatment complexity increases

Engineering Contradiction:

Improve treatment efficacyVSAvoidtreatment process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The CIK cell generation process is performed in advance (ex-vivo) before the actual treatment administration. Peripheral blood lymphocytes are collected, cultured with cytokines for 7-14 days to generate activated CIK cells, and then these pre-prepared cells are infused into the patient. This preliminary preparation allows for optimized cell activation and quality control before treatment

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

Cytokines (IL-2, IFN-gamma) and anti-CD3 antibodies serve as intermediary substances that mediate the transformation of peripheral blood lymphocytes into activated CIK cells. These intermediaries provide the necessary signaling and growth factors during the in vitro culture period, enabling the cells to acquire cytotoxic and immunomodulatory functions

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20240156871A1Cytokine-induced killer cells

Publication Date: 2024.05.16 ABTEILUNG FÜR INTEGRIERTE ONKOLOGIE - CIO BONN

AI summary

The present invention relates to cytokine induced Killer cells (CIKs) for use in the treatment of diseases caused by a Plasmodium infection.